What's Happening?
CROSSJECT, a specialty pharmaceutical company based in Dijon, France, has released its financial results for the year ending December 31, 2025. The company, known for its ZENEO® needle-free auto-injector technology, is advancing the development and registration
of ZEPIZURE®, an injectable for managing epileptic seizures. The financial report indicates a 12.25% increase in operating revenue, reaching €14.9 million, primarily driven by invoicing to BARDA. Despite a net loss of €10.4 million, this marks an improvement from the previous year's €12.8 million loss. The company has also reduced its bank debt by €2.7 million. CROSSJECT is actively pursuing regulatory preparation for an Emergency Use Authorization (EUA) application, supported by increased funding from BARDA, totaling $43.3 million. The company is also developing ZEPIZURE® Junior for pediatric use and has reported positive data on the ZENEO® platform's intramuscular performance.
Why It's Important?
CROSSJECT's financial and operational developments are significant for the pharmaceutical industry, particularly in the emergency medicine sector. The company's progress in needle-free injection technology could revolutionize the administration of emergency treatments, offering a safer and more efficient alternative to traditional methods. The increased funding from BARDA underscores the strategic importance of CROSSJECT's innovations in public health preparedness. The potential commercial success of ZEPIZURE® and other emergency medicines could significantly impact the company's market position and financial stability. Additionally, the focus on pediatric applications with ZEPIZURE® Junior highlights the company's commitment to addressing diverse patient needs, potentially expanding its market reach.
What's Next?
CROSSJECT aims to submit an EUA application for ZEPIZURE® as soon as possible, with plans to commence commercial deliveries to BARDA in 2026 and start U.S. commercialization in 2027. The company will continue to explore financing options to support its development activities, including equity financing, debt, and public funding. As CROSSJECT strengthens its operational and regulatory framework, it is poised to enhance its market visibility and financial structure, preparing for future growth and expansion in the emergency medicine market.
